These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 8208295)

  • 1. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice.
    Wang TC; Cardiff RD; Zukerberg L; Lees E; Arnold A; Schmidt EV
    Nature; 1994 Jun; 369(6482):669-71. PubMed ID: 8208295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transgenic mice with mammary gland targeted expression of human cortactin do not develop (pre-malignant) breast tumors: studies in MMTV-cortactin and MMTV-cortactin/-cyclin D1 bitransgenic mice.
    van Rossum AG; van Bragt MP; Schuuring-Scholtes E; van der Ploeg JC; van Krieken JH; Kluin PM; Schuuring E
    BMC Cancer; 2006 Mar; 6():58. PubMed ID: 16536875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
    Corsino P; Davis B; Law M; Chytil A; Forrester E; Nørgaard P; Teoh N; Law B
    Cancer Res; 2007 Apr; 67(7):3135-44. PubMed ID: 17409420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties.
    Bearss DJ; Lee RJ; Troyer DA; Pestell RG; Windle JJ
    Cancer Res; 2002 Apr; 62(7):2077-84. PubMed ID: 11929828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative mammary oncogenic pathways are induced by D-type cyclins; MMTV-cyclin D3 transgenic mice develop squamous cell carcinoma.
    Pirkmaier A; Dow R; Ganiatsas S; Waring P; Warren K; Thompson A; Hendley J; Germain D
    Oncogene; 2003 Jul; 22(28):4425-33. PubMed ID: 12853979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice.
    Lane TF; Leder P
    Oncogene; 1997 Oct; 15(18):2133-44. PubMed ID: 9393971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice.
    Kitsberg DI; Leder P
    Oncogene; 1996 Dec; 13(12):2507-15. PubMed ID: 9000125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation.
    Lovec H; Sewing A; Lucibello FC; Müller R; Möröy T
    Oncogene; 1994 Jan; 9(1):323-6. PubMed ID: 8302597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of cyclin D1 and p16(INK4A) is critical for growth arrest during mammary involution.
    Gadd M; Pisc C; Branda J; Ionescu-Tiba V; Nikolic Z; Yang C; Wang T; Shackleford GM; Cardiff RD; Schmidt EV
    Cancer Res; 2001 Dec; 61(24):8811-9. PubMed ID: 11751403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Happenstance, circumstance or enemy action: cyclin D1 in breast, eye and brain.
    Schmidt EV
    Bioessays; 1996 Jan; 18(1):6-8. PubMed ID: 8593165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53.
    Klein A; Guhl E; Tzeng YJ; Fuhrhop J; Levrero M; Graessmann M; Graessmann A
    Oncogene; 2003 May; 22(19):2910-9. PubMed ID: 12771941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional analysis of cyclin D2 and p27(Kip1) in cyclin D2 transgenic mouse mammary gland during development.
    Kong G; Chua SS; Yijun Y; Kittrell F; Moraes RC; Medina D; Said TK
    Oncogene; 2002 Oct; 21(47):7214-25. PubMed ID: 12370811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MMTV-Fgf8 transgenic mice develop mammary and salivary gland neoplasia and ovarian stromal hyperplasia.
    Daphna-Iken D; Shankar DB; Lawshé A; Ornitz DM; Shackleford GM; MacArthur CA
    Oncogene; 1998 Nov; 17(21):2711-7. PubMed ID: 9840935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression.
    Jiang W; Kahn SM; Zhou P; Zhang YJ; Cacace AM; Infante AS; Doi S; Santella RM; Weinstein IB
    Oncogene; 1993 Dec; 8(12):3447-57. PubMed ID: 8247550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis.
    Liao DJ; Natarajan G; Deming SL; Jamerson MH; Johnson M; Chepko G; Dickson RB
    Oncogene; 2000 Mar; 19(10):1307-17. PubMed ID: 10713672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterozygosity of p21WAF1/CIP1 enhances tumor cell proliferation and cyclin D1-associated kinase activity in a murine mammary cancer model.
    Jones JM; Cui XS; Medina D; Donehower LA
    Cell Growth Differ; 1999 Apr; 10(4):213-22. PubMed ID: 10319991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Notch1-induced mammary tumor development is cyclin D1-dependent and correlates with expansion of pre-malignant multipotent duct-limited progenitors.
    Ling H; Sylvestre JR; Jolicoeur P
    Oncogene; 2010 Aug; 29(32):4543-54. PubMed ID: 20562911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific protection against breast cancers by cyclin D1 ablation.
    Yu Q; Geng Y; Sicinski P
    Nature; 2001 Jun; 411(6841):1017-21. PubMed ID: 11429595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach.
    Nakagawa H; Wang TC; Zukerberg L; Odze R; Togawa K; May GH; Wilson J; Rustgi AK
    Oncogene; 1997 Mar; 14(10):1185-90. PubMed ID: 9121767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway.
    Akli S; Van Pelt CS; Bui T; Multani AS; Chang S; Johnson D; Tucker S; Keyomarsi K
    Cancer Res; 2007 Aug; 67(15):7212-22. PubMed ID: 17671189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.